|
| N-(2-methyl-5-nitrophenyl)-2-(4-oxoquinazolin-3(4H)-yl)acetamide |
|
Mycobacterium |
Immune modulation |
Preclinical (in vitro) |
Karanja CW, et al. 2021. ACS Infect Dis |
|
| N-(4-butylphenyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide |
|
Mycobacterium |
Exoenzyme |
Preclinical (in vitro) |
Chen L, et al. 2010. ACS Med Chem Lett |
|
| N-(5-chloro-2-methylphenyl)-2-(4-oxo-3(4H)-quinazolinyl)acetamide |
|
Mycobacterium |
Immune modulation |
Preclinical (in vitro) |
Karanja CW, et al. 2021. ACS Infect Dis |
|
H44
(internal name in literature) |
|
Mycobacterium |
Motility |
Preclinical (in vitro) |
Ouertatani-Sakouhi H, et al. 2017. PLoS One |
|
| Sepantronium bromide |
|
Escherichia
Salmonella |
TTSS secreted effectors
TTSS-2 secreted effectors |
Phase II trial
Preclinical (in vitro) |
El Qaidi S, et al. 2018. Front Cell Infect Microbiol; Zhu C, et al. 2021. Pathogens
|
|
| 4-chloro-N'-[(E)-(2-hydroxynaphthalen-1-yl)methylidene]benzohydrazide |
|
Chlamydia
Salmonella
Shigella |
TTSS (Type III secretion system)
TTSS (SPI-1 encode); TTSS (SPI-2 encode)
TTSS (Type III secretion system) |
Preclinical (in vitro)
Preclinical (in vitro)
Preclinical (in vitro) |
Muschiol S, et al. 2006. Proc Natl Acad Sci U S A
Negrea A, et al. 2007. Antimicrob Agents Chemother
Veenendaal AK, et al. 2009. J Bacteriol |
|
| 2-phenyl-2,3-dihydrophthalazine-1,4-dione |
|
Shigella |
VirF |
Preclinical (in vitro) |
Hurt JK, et al. 2010. J Biomol Screen |
|
| Plumbagin |
|
Staphylococcus |
Others; Biofilm |
Preclinical (in vitro) |
Nitulescu G, et al. 2019. Drug Dev Res |
|
Compound 1
(internal name in literature) |
|
Vibrio |
TCP (Toxin-coregulated pilus) |
Preclinical (in vitro) |
Woodbrey AK, et al. 2018. Biochemistry |
|
Compound 3
(internal name in literature) |
|
Vibrio |
TCP (Toxin-coregulated pilus) |
Preclinical (in vitro) |
Woodbrey AK, et al. 2018. Biochemistry |
|
| | | |
